



Haploidentical Transplantation 2014

Program Agenda

Intercontinental Hotel San Francisco
Thursday, December 4, 2014

7:00 AM – 8:00 AM — Registration and continental breakfast

8:00 AM - 8:30 AM — Opening Remarks: Stefan Ciurea, MD, Mary Horowitz, MD, and Richard Champlin, MD

Morning Sessions—Conditioning and Graft Manipulation - moderated by Richard Champlin, MD

8:30 AM – 11:45 AM — Presentations

- 8:30 AM **Stefan Ciurea, MD**, The University of Texas MD Anderson Cancer Center – Conditioning regimens for haploidentical transplantation with post-transplantation cyclophosphamide and comparative outcomes with matched transplantation
- 9:00 AM **Rupert Handgretinger, MD**, Children’s University Hospital, Tuebingen, Germany - Haploidentical transplantation as a platform for post-transplant immunotherapy
- 9:30 AM **Wing Leung, MD, PhD**, St. Jude Children’s Research Hospital – Graft manipulation using selective CR45RA depletion

10:00 AM to 10:15 AM Refreshment Break

- 10:15 AM **Denis Claude Roy, MD**, University of Montreal – Immunotherapy using T cells depleted of their alloreactive component
- 10:45 AM **Xiao-Jun Huang, MD**, Peking University Institute of Hematology – Haploidentical transplantation for AML/MDS
- 11:15 PM **Ephraim Fuchs, MD**, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center – Haploidentical transplantation with post-transplantation cyclophosphamide for hemoglobinopathies

11:45 AM to 1:15 PM - Lunch and short presentations - Ongoing and future clinical trials in haploidentical HSCT

- 12:15 PM **Ephraim Fuchs, MD** — Update on BMT CTN trials
- 12:25 PM **Franco Locatelli, MD, PhD** — Removal of alpha/beta T cells and B cells is a successful strategy for haplo HSCT in children with both malignant and nonmalignant disorders
- 12:35 PM **Hillard Lazarus, MD** — Update on the BPX-001 trial using iCasp9 suicide gene
- 12:45PM **Didier Blaise, MD** — Haplo vs. MUD transplants in the elderly
- 12:55PM **Shin Mineishi, MD** — Upcoming trial using gamma delta T cells for DLI
- 1:05 PM **Stefan Ciurea, MD** — Update on trial with mbIL-21 $ex-vivo$ expanded NK cells

Afternoon Sessions— Cell Therapy and Immune Reconstitution— moderated by Marcel van-den-Brink, MD, PhD

- 1:15 PM **Massimo Martelli, MD**, Perugia University — Haploidentical transplantation with adoptive Treg-Tcon immunotherapy
- 1:45 PM **Jeffrey Miller, MD**, University of Minnesota — NK cells and TCR alpha-beta depletion to enhance haploidentical transplantation
- 2:15 PM **Carl June, MD, PhD**, University of Pennsylvania — Cell therapy and potential applications in haploidentical transplantation

2:45 PM to 3:00 PM Refreshment Break

- 3:00 PM **Hui-Sheng Ai, MD**, Affiliated Hospital of Academy of Military Medical Sciences — HLA-haploidentical micro-transplantation
- 3:30 PM **Leo Luznik, MD**, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center — Immune reconstitution after allografting using post-transplant cyclophosphamide
- 4:00 PM **Enrico Lugli, PhD**, Humanitas Clinical and Research Center — Cellular mechanisms of T cell reconstitution following haploidentical transplantation
- 4:30 PM **Marcel van-den-Brink, MD, PhD**, Memorial Sloan Kettering Cancer Center — Strategies to enhance post-transplant immune reconstitution

5:00 PM Adjourn

Program organizers include the below institutions:



The program organizers extend their appreciation to
Bellicum Pharmaceuticals, Kiadis Pharma, and Miltenyi Biotec, Inc. for their support